ReviewOxidative medicine and cellular longevity2017
Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?
Review in Oxidative medicine and cellular longevity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 110 citations in OpenAlex.
- Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.Health technology assessment (Winchester, England) · 2025Trial
- Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study.International urology and nephrology · 2020Trial
- Low Ankle-Brachial Index in Patients on Hemodialysis Is Associated with Elevated Serum Levels of Spermine Oxidase and C-Reactive Protein.Life (Basel, Switzerland) · 2026Article
- Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease: From Molecular Mechanisms to Biomarkers and Targeted Therapies.Antioxidants (Basel, Switzerland) · 2026Review
- Redox Network Failure in Chronic Kidney Disease: Hydrogen Sulfide Deficiency, Reactive Sulfur Species Dysregulation and the Uremic Toxin-AhR-Mitochondrial Axis.Antioxidants (Basel, Switzerland) · 2026Review
- Gender-specific associations between serum indirect bilirubin and chronic kidney disease risk: a prospective cohort study highlighting a protective effect confined to males.BMC nephrology · 2026Article
- Association Between Physical Activity Levels and Mortality and Cardiovascular Disease in Chronic Kidney Disease: A Protocol for a Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Article
- Clarifying Molecular Mechanisms and Novel Strategies for Intervention of Uremia and Cognitive Decline.Kidney & blood pressure research · 2026Review
- The Clinical Utility and Plausibility of Oxidative and Antioxidant Variables in Chronic and End-Stage Kidney Disease: A Review of the Literature.International journal of molecular sciences · 2025Review
- Effect of N-Acetylcysteine in Mitochondrial Function, Redox Signaling, and Sirtuin 3 Levels in the Heart During Cardiorenal Syndrome Type 4 Development.Antioxidants (Basel, Switzerland) · 2025Article
- Differential Myocardial Responses in Male and Female Rats with Uremic Cardiomyopathy.International journal of molecular sciences · 2025Article
- Linking oxidative stress biomarkers to disease progression and antioxidant therapy in hypertension and diabetes mellitus.Frontiers in molecular biosciences · 2025Review
- The importance of paraoxonase 1 activity in chronic kidney disease.Renal failure · 2024Review
- Article
- Innovative Treatments to Counteract Endothelial Dysfunction in Chronic Kidney Disease Patients.Biomedicines · 2024Review
- Role of the kisspeptin-KISS1R axis in the pathogenesis of chronic kidney disease and uremic cardiomyopathy.GeroScience · 2024Article
- Knowledge landscapes and emerging trends of cardiorenal syndrome type 4: a bibliometrics and visual analysis from 2004 to 2022.International urology and nephrology · 2024Review
- The Role of Oxidative Stress in Kidney Injury.Antioxidants (Basel, Switzerland) · 2023Review
- Biotics (Pre-, Pro-, Post-) and Uremic Toxicity: Implications, Mechanisms, and Possible Therapies.Toxins · 2023Review
- Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats.JACC. Basic to translational science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) patients are among the groups at the highest risk for cardiovascular disease and significantly shortened remaining lifespan. CKD enhances oxidative stress in the organism with ensuing cardiovascular damage. Oxidative stress in uremia is the consequence of higher reactive oxygen species (ROS) production, whereas attenuated clearance of pro-oxidant substances and impaired antioxidant defenses play a complementary role. The pathophysiological mechanism underlying the increased ROS production in CKD is at least partly mediated by upregulation of the intrarenal angiotensin system. Enhanced oxidative stress in the setting of the uremic milieu promotes enzymatic modification of circulating lipids and lipoproteins, protein carbamylation, endothelial dysfunction via disruption of nitric oxide (NO) pathways, and activation of inflammation, thus accelerating atherosclerosis. Left ventricular hypertrophy (LVH) and heart failure are hallmarks of CKD. NADPH oxidase activation, xanthine oxidase, mitochondrial dysfunction, and NO-ROS are the main oxidative pathways leading to LVH and the cardiorenal syndrome. Finally, a subset of antioxidant enzymes, the paraoxonases (PON), deserves special attention due to abundant clinical evidence accumulated regarding reduced serum PON1 activity in CKD as a contributor to the increased burden of cardiovascular disease. Future, meticulously designed studies are needed to assess the effects of antioxidant therapy on patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.